A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
Status:
Completed
Trial end date:
2008-04-05
Target enrollment:
Participant gender:
Summary
GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being
developed for the treatment of rheumatoid arthritis. This study is being done in healthy
volunteers to verify the safety and tolerability of GSK182771